Finance

Lists
A1SN34:BVMF
Ascendis Pharma A/S Bdr
R$92.25
0.00%
(0.00) 1D
Sep 4, 4:24:30 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1SN34...
Mkt. cap
17.75B
Avg. vol.
54.00
Volume
0.00
52-wk high
R$94.05
52-wk low
R$69.30
Shares outstanding
62.38M
No. of employees
1K
Mkt. cap
17.75B
Avg. vol.
54.00
Volume
0.00
52-wk high
R$94.05
52-wk low
R$69.30
Shares outstanding
62.38M
No. of employees
1K
News stories
From web sources and news partners
About Ascendis Pharma A/S Bdr
CEO-
Employees1.19K
Founded2006
Headquarters-
SectorBiotechnology
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€0.90 / €0.77
+17.39%beat
Revenue / Est. (EUR)
339.28M / 329.90M
+2.84%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
213.63M
247.50M
246.60M
339.28M
Cost of goods sold
22.35M
23.60M
17.52M
27.66M
Cost of revenue
22.35M
23.60M
17.52M
27.66M
Research and development expenses
66.88M
82.20M
59.04M
75.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
113.40M
139.31M
145.23M
173.34M
Operating expense
180.28M
221.51M
204.27M
91.16M
Total operating expenses
202.64M
245.11M
221.79M
118.82M
Operating income
11.00M
2.39M
24.81M
220.46M
Other non operating income
-
-105.57M
-
-
EBT including unusual items
-57.37M
-26.70M
-48.18M
230.09M
EBT excluding unusual items
-57.37M
-34.21M
-48.18M
230.09M
Income tax expense
3.62M
6.86M
-677.52M
23.12M
Effective tax rate
-6.30%
-25.68%
1,406.31%
10.05%
Other operating expenses
-
-
-
-158.07M
Net income
-60.99M
-33.56M
629.34M
206.97M
Net profit margin
-28.55%
-13.56%
255.21%
61.00%
Earnings per share
-1.00
-0.55
0.27
0.90
Interest and investment income
6.04M
64.06M
4.52M
19.96M
Interest expense
-66.90M
-74.65M
-67.26M
-14.17M
Net interest expenses
-60.87M
-10.59M
-62.74M
5.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
15.02M
3.60M
29.03M
225.03M
Gain or loss from assets sale
-
-
-
21.00K
AI content may include mistakes. Learn more
Google apps